HAE

Haemonetics shares surged 149.3% over the past year, significantly outperforming the industry and S&P 500. The company's Plasma and MedSurg segments showed solid growth in Q1 fiscal 2027, with Plasma revenues up 7.2% and MedSurg up 6%. HAE raised its fiscal 2027 revenue guidance to 5-8%, but faces headwinds from high debt levels ($1.17 billion long-term debt) and competitive pressures.

Haemonetics Corporation (HAE), a blood management solutions provider, is highlighted as a stock to watch with a #3 (Hold) Zacks Rank and a B VGM Score. The stock has gained 14.8% over the past four weeks, driven by positive momentum. Two analysts revised earnings estimates upward in the last 60 days, with the Zacks Consensus Estimate increasing to $5.29 per share for fiscal 2027, and the company maintains a +6% average earnings surprise.

Haemonetics shares surged 17.5% following CSL's announcement of a supply agreement rollout across U.S. plasma collection centers by end of 2027. The company expects Q earnings of $1.30 per share (+2.4% YoY) with revenues of $346.84 million (+6% YoY).

However, analysts caution that without earnings estimate revisions, the stock may struggle to sustain momentum. HAE carries a Zacks Rank #3 (Hold).